Acadia Pharmaceuticals at a Glance

Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Rett syndrome and neuropsychiatric symptoms in central nervous system (CNS) disorders.

For more information visit us at Acadia.com or follow us on LinkedIn and Twitter.

ACADIA BY THE NUMBERS
Year Founded: 1993
Headquarters: San Diego, CA; Research and Development Center in Princeton, NJ
Employees: 500+

Corporate Milestones

MAY 2004  ●  Acadia completes its initial public offering and trades under the symbol “ACAD” on the Nasdaq Stock Market

APR 2016  ●  FDA approves NUPLAZID® (pimavanserin)

AUG 2018  ●  Acadia enters into exclusive North American license agreement with Neuren Pharmaceuticals Ltd. for the development and commercialization of trofinetide¹

NOV 2019  ●  Acadia announces top-line results from its ADVANCE study evaluating pimavanserin as a potential treatment for the negative symptoms of schizophrenia²

MAY 2020  ●  Acadia and Vanderbilt University announce exclusive license agreement and research collaboration to develop and commercialize novel drug candidates with potential to treat a range of central nervous system disorders

DEC 2021  ●  Acadia announces positive results from its pivotal LAVENDER™ study evaluating trofinetide¹

JAN 2022  ●  Acadia and Stoke Therapeutics establish collaboration to pursue multiple RNA-based treatments for severe and rare genetic neurodevelopmental diseases³

JUL 2022  ●  Acadia submits new drug application (NDA) to the FDA for trofinetide¹

MAR 2023  ●  FDA approves DAYBUE™ (trofinetide)¹

¹Acadia has an exclusive license to develop and commercialize trofinetide in North America from Neuren Pharmaceuticals. ²Safety and efficacy of pimavanserin for the treatment of negative symptoms of schizophrenia have not been established or approved by the FDA. ³Acadia entered into a collaboration with Stoke Therapeutics to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases.
Acadia Connect®

Acadia Connect a free support program to help patients navigate insurance approvals, manage costs, and guide patients, caregivers, and their healthcare providers to useful financial resources.

Those enrolled are paired with a dedicated Care Coordinator to offer insurance and prescription assistance. Visit AcadiaConnect.com for more information.

Marketed Products

Please see full prescribing information, including Boxed WARNING, also available at Nuplazidhcp.com

Please see full prescribing information available at Daybue.com1

Pipeline

Acadia’s neuroscience pipeline is focused on high unmet needs in CNS, including a growing focus on CNS rare diseases. Our pipeline spans late to early and preclinical developments.

Late Stage

- Development efforts focused on pimavanserin for the treatment of negative symptoms of schizophrenia2

Early Stage and Preclinical Programs

- Building upon the learnings of previous research in Alzheimer’s disease psychosis, Acadia is investing in a wholly-owned new molecule, currently in Phase 1
- Pursuing multiple RNA-based treatments for severe and rare genetic neurodevelopmental diseases through collaboration with Stoke Therapeutics3
- Developing a novel approach for improving cognitive function and other neuropsychiatric symptoms in patients with CNS disorders in collaboration with Vanderbilt University

Addressing Significant Unmet Needs in CNS

<table>
<thead>
<tr>
<th>Program</th>
<th>Indication</th>
<th>Preclinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Registration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pimavanserin2</td>
<td>Negative Symptoms of Schizophrenia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACP-2044</td>
<td>Alzheimer’s Disease Psychosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ASO Programs3</td>
<td>SYNGAP1; Rett Syndrome; Undisclosed</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other Programs</td>
<td>Neuropsychiatric Symptoms</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ASO = Antisense oligonucleotide.
Contains forward-looking statements; actual results may vary materially; Acadia disclaims any duty to update.

1 Acadia has an exclusive license to develop and commercialize trofinetide in North America from Neuren Pharmaceuticals. 2 Safety and efficacy of pimavanserin for the treatment of negative symptoms of schizophrenia have not been established or approved by the FDA. 3 Acadia entered into a collaboration with Stoke Therapeutics to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases. 4 ACP-204 is an investigational agent, and the safety and efficacy of this agent has not been established. There is no guarantee this investigational agent will be filed with or approved by any regulatory agency.

©2023 Acadia Pharmaceuticals Inc. Acadia, Acadia Connect, and NUPLAZID are registered trademarks and DAYBUE is a trademark of Acadia Pharmaceuticals Inc. All rights reserved. ACAD-0276 03/23